. Processing of proteome data. A. Protein coverage across all samples (n = 118). Protein expressed in 12 or fewer samples (10% cut-off) were removed (grey bars). 7141 proteins (black) remained for further analysis. B. Correlation between protein abundance and protein coverage. A high correlation (⍴ = 0.97) was observed after removing low abundance proteins. The red vertical indicates the 10% cutoff for low coverage proteins. C. Cook's distance across all samples. D. Density plot of the regularized log transformed proteomic data across all samples. (tumor samples in red, non-cancerous adjacent tissues in black). Figure S2 . Overlap in identified proteins between our study (Tang et al.) and other proteome datasets for breast cancer. We compared our list of quantified proteins with the list of proteins reported by Mertins et al., Pozniak et al., and Tyanova et al. in their breast cancer datasets. Overall 74% to 76% of the 7141 proteins in our study were also observed in each of the other studies. This overlap is very similar to the overlap comparing Mertins et al. with Tyanova et al. or Mertins et al. with Pozniak et al. Proteome data for Mertins et al., Pozniak et al., and Tyanova et al. were either downloaded via cbioportal from the Cancer Genomics Data Server (Mertins et al.) or obtained from supplementray files of the publications.
. Increased expression of proteins in breast tumors encoded by mRNAs with shortened 3'UTR. Xia et al. described 382 genes with significant 3'UTR mRNA shortening in human breast tumors due to alternative polyadenylation (APA). Of these genes, we could map 193 to proteins in our study and found that these proteins have an expression increase in breast tumors (vs. adjacent non-cancerous tissue) more so than other proteins [1.77 (mean) fold increase vs. 1.41 (mean) fold increase; Wilcoxon signed rank test P = 4.8x10 -6 ] (left panel), without the same increase in transcript levels (right panel), indicating that 3'UTR shortening leads to increased expression of proteins in breast tumors. Other mRNAs = mRNAs without alternative polyadenylation sites. Figure S5 . KEGG pathways that are significantly enriched for proteins and mRNAs that were differentially expressed between basal-like tumors and adjacent non-cancerous tissue (13 pairs). The red bars highlight KEGG pathways with enrichment for differentially expressed proteins without a similar enrichment for differentially expressed mRNAs. The grey bars indicate those pathways that were enriched for both differentially expressed proteins and mRNA in tumors. Several metabolism-and infection-related pathways were selectively enriched for differentially expressed proteins (mostly up-regulated in tumors). For the analysis, all proteins and mRNAs were ranked using Wald and t statistic and then imported into the GSEA pre-ranked module, KEGG pathway was selected as reference. KEGG pathway at a 5% FDR cutoff and |enrichment score (ES)| > 0.5 were included. Figure S6 . Robustness of the global protein-mRNA concordance estimates for breast tumors and adjacent non-cancerous tissues. A, Estimates of the global protein-mRNA concordance in breast tumors after random selection of proteome data subsets. We randomly selected 80% of the proteins from the full protein dataset and performed protein-mRNA correlation tests. The procedure was repeated 1000 times and visualized by a density plot with grey lines. Blue line shows the calculation using the full dataset. The global protein-mRNA concordance values between randomly selected subsets of data and the full dataset are very similar (r > 0.997), showing that the findings with the full dataset did not occur because of a random chance. B, Protein-mRNA concordance (Spearman's rho) differences between tumors (T) and adjacent non-cancerous tissues (N) are independent of protein abundance across samples. Shown are the concordances in relation to protein coverage with a consistently higher concordance in tumors across all coverage settings. PCT: Protein coverage from 15% to 85% in 5% increments. 15%: a protein in this group was detected in 15% or more of the tissues (tumor or adjacent non-cancerous tissues). 85%: a protein in this group was detected in at least 85% of the tissues. Delta: concordance differences between mean concordance in tumors and non-cancerous tissues. Red: tumor tissues; blue: non-cancerous tissues. Wilcoxon signed rank test. C, Density plot showing the global spearman correlation for protein-mRNA pairs in tumors and adjacent non-cancerous tissue. Only proteins that were expressed in both tumor and adjacent non-cancerous tissue were included in this analysis (n = 3095). Mean Spearman's correlation coefficient (rho) is 0.38 in tumors, which is significantly higher (P = 1.9x 10 -16 ) than the rho of 0.17 for adjacent non-cancerous tissues. D, same as B, but only proteins that were detectable in both tumors and adjacent non-cancerous tissues were included in this analysis. Heatmap representing NMF clustering of the tumor proteome data into two groups when only high variance proteins (MAD > 0.5) were included in the analysis. We applied the NMF algorithm to all tumors and selected the 1000 proteins with the highest expression variability for clustering (see methods). In the best-fit NMF model, two distinct groups of tumors emerged. Data were Z-score scaled with blue shaded blocks representing down-regulated proteins, those in red representing up-regulated proteins.
